我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
4
2 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
2
50.0%
招募中
1
25.0%
撤回
暂无批准数据
- Norwegian biotech Cytovation ASA has raised an additional $6 million from existing investors, bringing their total capital to $34 million to support Phase II trials of their cancer vaccine CY-101. - CY-101 is a novel membranolytic inhibitor that forms pores in cancer cells and inhibits the Wnt/β-catenin pathway, showing promising preclinical results in adrenocortical carcinoma, colorectal cancer, and melanoma. - The upcoming multi-center Phase II trial, conducted in partnership with Cancer Research UK, will focus on adrenocortical carcinoma patients with clinical readouts expected in 2026.
